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Extensively hydrolysed infant 
formulas: Need for aligned definition 
of peptide size characteristics and 
standardisation of analytical methods
To the Editor: We read with interest the publication by Levin et al.[1] 
on the peptide composition and potential residual allergenicity of 
a range of speciality infant formulas. This publication is topical, 
as current cow’s milk protein allergy guidelines have provided 
relatively little detail on the molecular specifications and technical 
requirements of extensively hydrolysed formulas (EHFs).[2-5] 
Currently, significant differences exist in the peptide composition 
of marketed EHFs which are thought to be the basis for observed 
differences in their clinical tolerability.[6,7] Some EHFs with a 
comparatively high residual allergen content may be associated with 
a significant rate of allergic reactions; however, their exact allergen 
contents and peptide profiles are generally not publicly disclosed. 
For this reason, providing published information on the degree of 
hydrolysis and residual allergen content in EHFs is welcome and 
will assist clinicians in selecting a hypoallergenic formula with a low 
residual allergen content.
Levin et al.[1] evaluated several EHFs and amino acid-based 
formulas (AAFs) available in South Africa (SA) for their residual 
allergen content, peptide size profile and amino acid content. 
EHFs are manufactured by extensive enzymatic hydrolysis, heat 
denaturation and sometimes ultrafiltration, which eliminates the 
vast majority of allergenic peptides. Conversely, AAFs are not 
prepared by hydrolysis and contain free amino acids, but no 
residual cow’s milk-derived peptides. We were intrigued to see some 
large differences and high values obtained for peptide compounds 
between 1.5 and 3 kDa in a range of EHFs and AAFs, as summarised 
in Table 2 of the publication. Levin et al.[1] report values for Alfaré, 
a whey-based EHF, which are in stark contradiction to our own 
analytical results. Based on area under the curve (AUC) data 
provided, they found 14% peptides of 1.5 - 3 kDa in size for Alfaré, 
compared with <2% of peptides >1.2 kDa found by our internal 
analyses.[8] In addition, several AAFs were reported as having a 
significant content of larger peptides, which is not plausible given 
the manufacturing process from single amino acids. We speculate 
that the detection of larger peptides in EHFs and AAFs may be due 
to an analysis artefact, possibly relating to residual starches or fat in 
formula samples.
In conclusion, we congratulate the authors on addressing the 
heterogeneity of EHFs in terms of residual allergen content and 
peptide composition. However, we question the validity of the 
reported content of larger peptides (1.5 - 3 kDa) in EHFs and AAFs. 
The study highlights the need for standardisation of analytical 
methods in the quantification of the residual allergen content in 
hypoallergenic formulas. Furthermore, formal consensus is required 
on the definition and technical requirements of EHFs with regard 
to peptide molecular weight profile and proportion of peptides 
>1.2  kDa. Importantly, while molecular peptide characteristics 
of EHFs may suggest hypoallergenicity, these findings need to be 
assessed by rigorous clinical trials demonstrating tolerance in at 
least 90% of cow’s milk-allergic children by double-blind, placebo-
controlled food challenge, in line with the guidance provided by the 
American Academy of Pediatrics.[2]
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Levin et al. respond: We welcome the interest in and comments on 
the analysis we performed on the various milk formulas available 
in SA. We agree that nutrition, especially in the young, is most 
important and that standardisation of methods is very important. 
As dedicated laboratories are not available in SA, the analysis was 
done in a research laboratory setting and with such methods as were 
available to answer the question about the suitability of the various 
milk formulas for patients. As indicated in the results section for 
high-performance liquid chromatography, the ultraviolet absorption 
wavelength is not necessarily specific. The AUC for the molecular 
size range of peptides lacked specific peaks that might have prompted 
us to investigate this region in more detail. This was corroborated by 
the lack of fluorescent derivatives of carboxylic acid moieties on the 
gel. Since we were confident that all products appeared satisfactory, 
we did not investigate the difference in the AUC in the small-peptide 
region any further. We agree that the additional AUC may be due to 
other substances.
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